Adalimumab biosimilar(Aprogen)

阿达木单抗生物类似药（Aprogen）

Report date: 2022/03/16 10:22:21

Base Information

Drug NameAdalimumab biosimilar(Aprogen)

Drug Alias NameAdalimumabum biosimilar(Aprogen)阿达利单抗生物类似药Humira biosimilar(Aprogen)阿达利木单抗生物类似药阿达莫单抗生物类似药 +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAprogen

China Registration ClassN/A

Active CompaniesAprogen

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

ATC CodeN/A